leisure time -WSS

leisure time

author：comprehensive 2025-09-28 02:32:47 - browse：2264

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

leisure time

WSS

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

CRISPR gene editing developments we’re watching in 2024

Why health care costs have stayed mostly flat since 2010

Wikipedia

leisure time

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Intellia reports positive results for its CRISPR

Continuity nursing helped my family in our darkest PICU moments

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Affirmative action in medical school literally saved lives

How to increase colonoscopy rates? Looks like an AI can help

Apple is now the first public company to be valued at $3 trillion

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Drug repurposing or repositioning? The language matters

Albert Bourla of Pfizer: worst biopharma CEO of 2023

focus

See how much Covid

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Why health records don't always know when patients are dead

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Kaiser's Risant Health gobbled up Geisinger. Who is next?

explore

leisure time

leisure time

knowledge